Clinical trials for medicines: MHRA phase I accreditation scheme

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) oversees a voluntary Phase I accreditation scheme for organizations conducting early-stage clinical trials, particularly First in Human (FIH) studies. This initiative aims to enhance trial safety and foster public confidence by requiring participating units to exceed basic Good Clinical Practice (GCP) standards. To maintain accreditation, organizations must implement rigorous procedures for minimizing participant harm and managing medical emergencies effectively. The regulatory framework is built upon established GCP principles, supplemented by specific safety criteria detailed in the MHRA's accreditation guidance. While the provided document does not list specific violations or inspection dates—as it serves as a general framework rather than an inspection report—it emphasizes that strict adherence to these higher safety standards is mandatory for accreditation. Required actions for organizations include submitting a comprehensive compliance checklist and ensuring that Principal Investigators meet specific postgraduate qualification requirements. Those with significant experience but lacking formal qualifications may seek an exemption through an independent review by the Faculty of Pharmaceutical Medicine. This structured approach ensures that complex clinical trials are conducted under the highest possible safety oversight.